Nucleome Therapeutics

Nucleome Therapeutics is a biotechnology company founded in 2019, with a focus on utilizing 3D genomics for discovering precision medicines targeted at complex diseases, particularly in the field of inflammatory conditions. The company's 3D genomics technology has the potential to significantly enhance drug discovery success rates by identifying genetically-validated medicines and accurately pinpointing patients likely to benefit from treatments.

The company, based in the United Kingdom, boasts a platform that can be applied to multiple disease indications and cell types, thus widening its potential impact. In addition to advancing its own pipeline, Nucleome Therapeutics is actively seeking partnerships in target discovery, target validation, and patient stratification.

Backed by a distinguished group of investors, including M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson & Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises, Nucleome secured a noteworthy £37.50M Series A investment on 19 October 2022.

The company's distinguished pool of investors and specialized approach to drug discovery positions Nucleome Therapeutics as a potential frontrunner in the biotechnology sector, addressing unmet needs in the field of precision medicine.